Skip to main content
. Author manuscript; available in PMC: 2012 Sep 10.
Published in final edited form as: Ann Surg. 2010 Mar;251(3):470–476. doi: 10.1097/SLA.0b013e3181cf8a19

FIGURE 3.

FIGURE 3

The favorable survival after resection of IPMN-associated invasive adenocarcinoma (dotted line) compared with standard ductal adenocarcinoma (continuous line) was mainly noted in patients with node negative (N0) disease (median survival, 92 vs. 25 months) and T1 tumors (median survival, not reached vs. 26 months). However, in patients with node positive disease (N1, 20 vs. 18 months) and tumors >2 cm and/or extrapancreatic extension, survival outcomes were similar (median, T2: 45 vs. 34 months; T3: 23 vs. 19 months; T4: 19 vs. 10 months).